Literature DB >> 32386415

Patients With Natural Killer (NK) Cell Chronic Active Epstein-Barr Virus Have Immature NK Cells and Hyperactivation of PI3K/Akt/mTOR and STAT1 Pathways.

Matthew K Howe1, Kennichi Dowdell1, Hye Sun Kuehn2, Qingxue Li1, Geoffrey T Hart3, Doreen Garabedian4, Kelly Liepshutz4, Amy P Hsu5, Hua Su5, Julie E Niemela2, Jennifer L Stoddard2, Gulbu Uzel5, Evan Shereck6, Laura Schulz7, Tatyana Feldman8, Sergio D Rosenzweig2, Eric O Long3, Lesia Dropulic1, Jeffrey I Cohen1.   

Abstract

BACKGROUND: Chronic active Epstein-Barr virus (CAEBV) presents with high levels of viral genomes in blood and tissue infiltration with Epstein-Barr virus (EBV)-positive lymphocytes. The pathogenesis of CAEBV is poorly understood.
METHODS: We evaluated 2 patients with natural killer (NK) cell CAEBV and studied their NK cell phenotype and signaling pathways in cells.
RESULTS: Both patients had increased numbers of NK cells, EBV predominantly in NK cells, and immature NK cells in the blood. Both patients had increased phosphorylation of Akt, S6, and STAT1 in NK cells, and increased total STAT1. Treatment of 1 patient with sirolimus reduced phosphorylation of S6 in T and B cells, but not in NK cells and did not reduce levels of NK cells or EBV DNA in the blood. Treatment of both patients' cells with JAK inhibitors in vitro reduced phosphorylated STAT1 to normal. Patients with T- or B-cell CAEBV had increased phosphorylation of Akt and S6 in NK cells, but no increase in total STAT1.
CONCLUSIONS: The increase in phosphorylated Akt, S6, and STAT1, as well as immature NK cells describe a new phenotype for NK cell CAEBV. The reduction of STAT1 phosphorylation in their NK cells with JAK inhibitors suggests a novel approach to therapy. Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Entities:  

Keywords:  Akt; Epstein-Barr virus; NK cells; STAT1; chronic active EBV

Year:  2020        PMID: 32386415      PMCID: PMC7459139          DOI: 10.1093/infdis/jiaa232

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  The Epstein-Barr virus SM protein induces STAT1 and interferon-stimulated gene expression.

Authors:  Vivian Ruvolo; Lorena Navarro; Clare E Sample; Michael David; Seung Sung; Sankar Swaminathan
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.

Authors:  Giovanna Tabellini; Donatella Vairo; Omar Scomodon; Nicola Tamassia; Rosalba Monica Ferraro; Ornella Patrizi; Sara Gasperini; Annarosa Soresina; Giuliana Giardino; Claudio Pignata; Vassilios Lougaris; Alessandro Plebani; Laura Dotta; Marco A Cassatella; Silvia Parolini; Raffaele Badolato
Journal:  J Allergy Clin Immunol       Date:  2017-01-06       Impact factor: 10.793

3.  Latent membrane protein 1 regulates STAT1 through NF-kappaB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells.

Authors:  Imen Najjar; Fanny Baran-Marszak; Christophe Le Clorennec; Christelle Laguillier; Olivier Schischmanoff; Ibtissam Youlyouz-Marfak; Martin Schlee; Georg W Bornkamm; Martine Raphaël; Jean Feuillard; Remi Fagard
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.

Authors:  Katja G Weinacht; Louis-Marie Charbonnier; Fayhan Alroqi; Ashley Plant; Qi Qiao; Hao Wu; Clement Ma; Troy R Torgerson; Sergio D Rosenzweig; Thomas A Fleisher; Luigi D Notarangelo; Imelda C Hanson; Lisa R Forbes; Talal A Chatila
Journal:  J Allergy Clin Immunol       Date:  2017-01-27       Impact factor: 10.793

5.  Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

Authors:  Jeffrey I Cohen; Elaine S Jaffe; Janet K Dale; Stefania Pittaluga; Helen E Heslop; Cliona M Rooney; Stephen Gottschalk; Catherine M Bollard; V Koneti Rao; Adriana Marques; Peter D Burbelo; Siu-Ping Turk; Rachael Fulton; Alan S Wayne; Richard F Little; Mitchell S Cairo; Nader K El-Mallawany; Daniel Fowler; Claude Sportes; Michael R Bishop; Wyndham Wilson; Stephen E Straus
Journal:  Blood       Date:  2011-03-31       Impact factor: 22.113

Review 6.  The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside.

Authors:  XueQiao Liu; Jeffrey I Cohen
Journal:  Virology       Date:  2015-03-20       Impact factor: 3.616

7.  Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome.

Authors:  Gulbu Uzel; Elizabeth P Sampaio; Monica G Lawrence; Amy P Hsu; Mary Hackett; Morna J Dorsey; Richard J Noel; James W Verbsky; Alexandra F Freeman; Erin Janssen; Francisco A Bonilla; Joseph Pechacek; Prabha Chandrasekaran; Sarah K Browne; Anahita Agharahimi; Ahmed M Gharib; Sara C Mannurita; Jae Joon Yim; Eleonora Gambineri; Troy Torgerson; Dat Q Tran; Joshua D Milner; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2013-03-25       Impact factor: 10.793

8.  Fatal combined immunodeficiency associated with heterozygous mutation in STAT1.

Authors:  Nigel Sharfe; Amit Nahum; Andrea Newell; Harjit Dadi; Bo Ngan; Sergio L Pereira; Jo-Anne Herbrick; Chaim M Roifman
Journal:  J Allergy Clin Immunol       Date:  2013-11-13       Impact factor: 10.793

9.  Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1.

Authors:  Lies Boelen; Bisrat Debebe; Marcos Silveira; Arafa Salam; Julia Makinde; Chrissy H Roberts; Eddie C Y Wang; John Frater; Jill Gilmour; Katie Twigger; Kristin Ladell; Kelly L Miners; Jyothi Jayaraman; James A Traherne; David A Price; Ying Qi; Maureen P Martin; Derek C Macallan; Chloe L Thio; Jacquie Astemborski; Gregory Kirk; Sharyne M Donfield; Susan Buchbinder; Salim I Khakoo; James J Goedert; John Trowsdale; Mary Carrington; Simon Kollnberger; Becca Asquith
Journal:  Sci Immunol       Date:  2018-11-09

10.  Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.

Authors:  Ivan Angulo; Oscar Vadas; Fabien Garçon; Edward Banham-Hall; Vincent Plagnol; Timothy R Leahy; Helen Baxendale; Tanya Coulter; James Curtis; Changxin Wu; Katherine Blake-Palmer; Olga Perisic; Deborah Smyth; Mailis Maes; Christine Fiddler; Jatinder Juss; Deirdre Cilliers; Gašper Markelj; Anita Chandra; George Farmer; Anna Kielkowska; Jonathan Clark; Sven Kracker; Marianne Debré; Capucine Picard; Isabelle Pellier; Nada Jabado; James A Morris; Gabriela Barcenas-Morales; Alain Fischer; Len Stephens; Phillip Hawkins; Jeffrey C Barrett; Mario Abinun; Menna Clatworthy; Anne Durandy; Rainer Doffinger; Edwin R Chilvers; Andrew J Cant; Dinakantha Kumararatne; Klaus Okkenhaug; Roger L Williams; Alison Condliffe; Sergey Nejentsev
Journal:  Science       Date:  2013-10-17       Impact factor: 47.728

View more
  1 in total

Review 1.  Regulation of the human NK cell compartment by pathogens and vaccines.

Authors:  Martin R Goodier; Eleanor M Riley
Journal:  Clin Transl Immunology       Date:  2021-01-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.